ClinicalTrials.gg
Not yet recruitingNCT07942402UROCULTURPUpdated Nov 17, 2026

Impact of Preoperative Urine Culture Following Transurethral Resection of the Prostate (UROCULTURP).

An interventional study of Knowledge of Preoperative Urine Culture Results and Blinding to Preoperative Urine Culture Results in Prostatic Hyperplasia, Benign, Urinary Infection and Bacteriuria Asymptomatic, sponsored by Universidad de Antioquia. Not yet recruiting at 1 site in Colombia. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Universidad de Antioquia · Not applicable, Interventional, and Diagnostic

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,262
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Benign prostatic hyperplasia (BPH) is a common condition in men, and a proportion of affected patients require surgical treatment. Transurethral resection of the prostate (TURP) is considered the gold standard for the surgical management of these patients. Preoperative asymptomatic bacteriuria (ASB) is present in approximately 30% of patients with BPH undergoing TURP. Current guidelines recommend screening for and treating ASB before endoscopic urological procedures associated with mucosal trauma to prevent postoperative infectious complications. However, the precise role of ASB in the development of postoperative urinary tract infections (UTIs) remains unclear, and the quality of the evidence supporting these recommendations is low.

A prospective, comparative clinical study is therefore warranted to determine the effectiveness of preoperative screening for and treatment of ASB in preventing infectious complications in patients with BPH undergoing TURP. The findings may help address existing knowledge gaps, inform future recommendations, and promote adherence to evidence-based clinical decision-making.

The objective of this study is to determine the effectiveness of preoperative screening for and treatment of ASB in preventing postoperative infectious complications in patients with BPH undergoing TURP.

A multicenter, parallel-group, randomized non-inferiority diagnostic test trial is proposed. A total of 1,262 men aged over 45 years with a diagnosis of BPH, an indication for TURP due to BPH, and no signs or symptoms of UTI will be enrolled. Participants will be randomly assigned in a 1:1 ratio to one of two groups according to whether the results of the preoperative urine culture are disclosed or withheld. Participants will be followed up for one month, and the primary outcome will be the occurrence of urinary tract infection (UTI).

The study was approved for review by the Research Ethics Committee of the Faculty of Medicine at the University of Antioquia and by the ethics committees of all participating institutions involved in patient recruitment.

02

Conditions studied

  • Prostatic Hyperplasia, Benign
  • Urinary Infection
  • Bacteriuria Asymptomatic
  • TURP(Transurethral Resection of Prostate)
  • Transurethral Prostatectomy
  • Transurethral Resection of Prostate
03

In context

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

This study's planned enrollment of 1,262 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.

Browse Prostatic Hyperplasia studies →

Lead sponsor

Universidad de Antioquia is the lead sponsor of 80 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged >45 years with a diagnosis of benign prostatic hyperplasia (BPH).
  • Indication for transurethral resection of the prostate (TURP) for BPH.
  • Absence of signs or symptoms of urinary tract infection (UTI).

Exclusion criteria

Exclusion Criteria:

  • Symptomatic urinary tract infection (UTI) or antibiotic treatment within the previous month for a UTI or any other infectious condition.
  • Patients scheduled to undergo additional transurethral procedures during the same surgical session (e.g., urethrotomy, transurethral resection of a bladder tumor [TURBT], or cystolithotomy).
  • Diagnosis of prostate cancer.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
1,262 participants (estimated)

Study arms

  • Other
    Disclosure Group

    Disclosure of preoperative urine culture results

    Other: Knowledge of Preoperative Urine Culture Results

  • Other
    Non-Disclosure Group

    Non-disclosure of preoperative urine culture results

    Other: Blinding to Preoperative Urine Culture Results

Interventions

  • OtherKnowledge of Preoperative Urine Culture Results

    In this arm, the results of the preoperative urine culture will be made available to the treating urologist.

  • OtherBlinding to Preoperative Urine Culture Results

    In this arm, the results of the preoperative urine culture will not be made available to the treating urologist.

06

What researchers measure

Primary outcomes

  1. Urinary tract infection (UTI)

    UTI was defined according to the American Urological Association (AUA) antimicrobial prophylaxis guidelines (43), supplemented by the European Association of Urology (EAU) UTI diagnostic criteria (10). Patients were classified as having a UTI if they met any of 4 scenarios: (1) ≥1 urinary symptom or fever, positive urine culture (\>10⁵ CFU), and surgeon-confirmed post-endoscopic UTI; (2) ≥2 urinary symptoms or fever plus supportive laboratory findings or clinical diagnosis; (3) postoperative fever with imaging suggestive of pyelonephritis after TURP, or catheter-associated UTI with ≥10³ CFU/mL within the specified catheterization period; or (4) ≥2 persistent urinary symptoms for \>1 week after catheter removal, without fever or improvement, plus positive urine culture (\>10⁵ CFU) and surgeon-confirmed post-endoscopic UTI.

    Time frame: 30 days or 1 month

Secondary outcomes

  1. Urinary sepsis

    Patients will be diagnosed with rrinary sepsis if they meet the criteria: * The patient has a recognized pathogen cultured from one or more blood culture specimens; AND * The organism isolated from the blood is not associated with an infection at another site; AND * The patient presents with at least one of the following signs or symptoms: fever (\>38 °C), chills, hypotension or septic shock, or organ dysfunction; AND * The signs and symptoms, as well as the positive laboratory findings, are not attributable to an infection at another site. In clinical practice, organ dysfunction may be indicated by a Quick Sequential Organ Failure Assessment (qSOFA) score of ≥2. The qSOFA criteria are a respiratory rate of ≥22 breaths/min, altered mental status, or systolic blood pressure of ≤100mmHg. Septic shock will be defined as the requirement for vasopressors to maintain a mean arterial pressure of ≥65 mmHg, together with a serum lactate level of \>2 mmol/L(\>18 mg/dL), in the absence of hypovolemia

    Time frame: 30 days or 1 month

  2. Acute orchiepididymitis

    Acute orchiepididymitis will be defined as the presence of scrotal pain, swelling, increased temperature, and inflammatory changes, accompanied by testicular and/or epididymal tenderness and enlargement on palpation; or inflammatory changes involving the testis and/or epididymis, with increased blood flow on color Doppler ultrasonography, with or without intratesticular collections on ultrasound examination. These findings may occur regardless of whether the urine culture is positive.

    Time frame: 30 days or 1 month

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.

Of 153 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's planned 36 months is above that.

Counting every sponsor, half of 205 studies reached it within 26 months; a quarter within 15 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Nov 1, 2029
CompletionEst.
Jun 1, 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942402
Lead sponsor
Universidad de Antioquia
Responsible party
Francisco Luis Caro Zapata (MD, Urologist, Doctoral Student, Universidad de Antioquia) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2029 (estimated)
Completion
Jun 1, 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

Francisco L Caro, MD, Urologist
Contact
francisco.caro@udea.edu.co
+57 604-219-8332
Ivan D Florez, MD, MSc, PhD
Contact
ivan.florez@udea.edu.co
+57 313 7421132
Francisco L Caro, MD, Urologist
principal investigator · Universidad de Antioquia
Ivan D Florez, MD, MSc, PhD
study director · Universidad de Antioquia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion